Cargando…
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
BACKGROUND: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of th...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443306/ https://www.ncbi.nlm.nih.gov/pubmed/32819974 http://dx.doi.org/10.1136/jitc-2020-000979 |
_version_ | 1783573609010167808 |
---|---|
author | Hensler, Michal Kasikova, Lenka Fiser, Karel Rakova, Jana Skapa, Petr Laco, Jan Lanickova, Tereza Pecen, Ladislav Truxova, Iva Vosahlikova, Sarka Moserova, Irena Praznovec, Ivan Drochytek, Vit Rehackova, Martina Brtnicky, Tomas Rob, Lukas Benes, Vladimir Pistolic, Jelena Sojka, Ludek Ryska, Ales Sautes-Fridman, Catherine Fridman, Wolf Herve Galluzzi, Lorenzo Spisek, Radek Fucikova, Jitka |
author_facet | Hensler, Michal Kasikova, Lenka Fiser, Karel Rakova, Jana Skapa, Petr Laco, Jan Lanickova, Tereza Pecen, Ladislav Truxova, Iva Vosahlikova, Sarka Moserova, Irena Praznovec, Ivan Drochytek, Vit Rehackova, Martina Brtnicky, Tomas Rob, Lukas Benes, Vladimir Pistolic, Jelena Sojka, Ludek Ryska, Ales Sautes-Fridman, Catherine Fridman, Wolf Herve Galluzzi, Lorenzo Spisek, Radek Fucikova, Jitka |
author_sort | Hensler, Michal |
collection | PubMed |
description | BACKGROUND: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases. METHODS: RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8(+) T cells, CD20(+) B cells, DC-LAMP(+) (lysosomal-associated membrane protein 3) dendritic cells (DCs), NKp46(+) (natural killer) cells and CD68(+)CD163(+) M2-like tumor-associated macrophages (TAMs), abundance of PD-1(+) (programmed cell death 1), LAG-3(+) (lymphocyte-activating gene 3) cells, and PD-L1 (programmed death ligand 1) expression in 80 samples. Flow cytometry was used for functional assessments on freshly resected HGSC samples. RESULTS: 1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome. CONCLUSIONS: Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs. |
format | Online Article Text |
id | pubmed-7443306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-74433062020-08-28 M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer Hensler, Michal Kasikova, Lenka Fiser, Karel Rakova, Jana Skapa, Petr Laco, Jan Lanickova, Tereza Pecen, Ladislav Truxova, Iva Vosahlikova, Sarka Moserova, Irena Praznovec, Ivan Drochytek, Vit Rehackova, Martina Brtnicky, Tomas Rob, Lukas Benes, Vladimir Pistolic, Jelena Sojka, Ludek Ryska, Ales Sautes-Fridman, Catherine Fridman, Wolf Herve Galluzzi, Lorenzo Spisek, Radek Fucikova, Jitka J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases. METHODS: RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8(+) T cells, CD20(+) B cells, DC-LAMP(+) (lysosomal-associated membrane protein 3) dendritic cells (DCs), NKp46(+) (natural killer) cells and CD68(+)CD163(+) M2-like tumor-associated macrophages (TAMs), abundance of PD-1(+) (programmed cell death 1), LAG-3(+) (lymphocyte-activating gene 3) cells, and PD-L1 (programmed death ligand 1) expression in 80 samples. Flow cytometry was used for functional assessments on freshly resected HGSC samples. RESULTS: 1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome. CONCLUSIONS: Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs. BMJ Publishing Group 2020-08-20 /pmc/articles/PMC7443306/ /pubmed/32819974 http://dx.doi.org/10.1136/jitc-2020-000979 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Immunotherapy Biomarkers Hensler, Michal Kasikova, Lenka Fiser, Karel Rakova, Jana Skapa, Petr Laco, Jan Lanickova, Tereza Pecen, Ladislav Truxova, Iva Vosahlikova, Sarka Moserova, Irena Praznovec, Ivan Drochytek, Vit Rehackova, Martina Brtnicky, Tomas Rob, Lukas Benes, Vladimir Pistolic, Jelena Sojka, Ludek Ryska, Ales Sautes-Fridman, Catherine Fridman, Wolf Herve Galluzzi, Lorenzo Spisek, Radek Fucikova, Jitka M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer |
title | M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer |
title_full | M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer |
title_fullStr | M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer |
title_full_unstemmed | M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer |
title_short | M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer |
title_sort | m2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer |
topic | Immunotherapy Biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443306/ https://www.ncbi.nlm.nih.gov/pubmed/32819974 http://dx.doi.org/10.1136/jitc-2020-000979 |
work_keys_str_mv | AT henslermichal m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT kasikovalenka m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT fiserkarel m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT rakovajana m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT skapapetr m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT lacojan m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT lanickovatereza m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT pecenladislav m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT truxovaiva m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT vosahlikovasarka m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT moserovairena m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT praznovecivan m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT drochytekvit m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT rehackovamartina m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT brtnickytomas m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT roblukas m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT benesvladimir m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT pistolicjelena m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT sojkaludek m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT ryskaales m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT sautesfridmancatherine m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT fridmanwolfherve m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT galluzzilorenzo m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT spisekradek m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer AT fucikovajitka m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer |